High‐sensitive clinical diagnostic method for PTPRZ1‐MET and the characteristic protein structure contributing to ligand‐independent MET activation

BACKGROUND: PTPRZ1‐MET (ZM) is a critical genetic alteration driving the progression of lower‐grade glioma. Glioma patients harboring ZM could benefit from MET inhibitors. According to the remarkable role of ZM as a driver of glioma progression and indicator of MET inhibitor sensitivity, it is neces...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ruoyu, Liu, Yanwei, Wang, Kuanyu, Wang, Zheng, Zhang, Chuanbao, Zhang, Wei, Zhao, Zheng, Li, Guanzhang, Huang, Lijie, Chang, Yuanhao, Zeng, Fan, Jiang, Tao, Hu, Huimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025647/
https://www.ncbi.nlm.nih.gov/pubmed/33645009
http://dx.doi.org/10.1111/cns.13627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025647/
https://www.ncbi.nlm.nih.gov/pubmed/33645009
http://dx.doi.org/10.1111/cns.13627

Ejemplares similares